Stocktoria

ONCOLYTICS BIOTECH INC ONCY

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2001-10-05

ONCOLYTICS BIOTECH INC financials (annual)

Revenue
20242025
Net income
-$22.8M -$28.8M 20242025
Free cash flow
-$20.1M -$20.1M 20242025

Bars are annual figures from 2024 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024
R&D expense$13.3M$15.4M
Operating income-$28.7M-$25.5M
Income tax$79,000$95,000
Net income-$28.8M-$22.8M
EPS (diluted)$-0.30$-0.30
Operating cash flow-$20.1M-$19.9M
Free cash flow-$20.1M-$20.1M
Cash & equivalents$5.2M$11.1M
Total assets$7.6M$13.4M
Total liabilities$11.4M$10.1M
Shareholders' equity-$3.8M$3.3M

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.